VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
PDF Celotno besedilo
  • Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer [Elektronski vir] : final analysis of the GioTag study
    Hochmair, Maximilian J ...
    Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & ... methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
    Vir: Future oncology. - ISSN 1744-8301 (Vol. 16, iss. 34, Dec. 2020, str. 2799-2808)
    Vrsta gradiva - e-članek ; neleposlovje za odrasle
    Leto - 2020
    Jezik - angleški
    COBISS.SI-ID - 37424899